Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Health, ...

Josephs joins forces with LifeRx.md to redefine health through doctor-led GLP‑1 wellness programs—merging celeb credibility ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Dr. Mahsa Tehrani discusses how patients use medication to help them lose weight on 'America Reports.' ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Instant ramen maker Nissin Foods is leveraging the buzz around GLP-1s to launch in the US a trio of decadent tasting frozen ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.